Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GATA1
REST API REST API
Homo sapiens
GATA1 is differentially expressed in 173 experiments: 49 organism parts: bone marrow, liver, ... (47 more);, 118 disease states: normal, chronic myelogenous leukemia, ... (116 more);, 58 cell types 98 cell lines 20 compound treatments and 61 other conditions.
Synonyms GF1, NFE1, GATA-1, ERYF1
Orthologs Gata1 (Rattus norvegicus)   Q4H3F5_CIOIN (Ciona intestinalis)   GATA1 (Bos taurus)   DAL80 (Saccharomyces cerevisiae)   gata1a (Danio rerio)   Gata1 (Mus musculus)   GAT1 (Saccharomyces cerevisiae)   GZF3 (Saccharomyces cerevisiae)   GLN3 (Saccharomyces cerevisiae)   grn (Drosophila melanogaster)   gata1b (Danio rerio)   gata1 (Xenopus laevis)   GATA1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term transcriptional repressor complex, DNA binding, protein binding, regulation of transcription, DNA-dependent, negative regulation of cell proliferation, negative regulation of apoptosis, metal ion binding, male gonad development, DNA bending activity, cell-cell signaling, blood coagulation, transcription from RNA polymerase II promoter, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, nucleus, transcription factor complex, chromatin binding, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, embryonic hemopoiesis, nucleolus, nuclear membrane, zinc ion binding, platelet aggregation, cellular response to cAMP, erythrocyte development, in utero embryonic development, positive regulation of peptidyl-tyrosine phosphorylation, cellular response to follicle-stimulating hormone stimulus, C2H2 zinc finger domain binding, erythrocyte differentiation, platelet formation, positive regulation of anti-apoptosis, regulation of glycoprotein biosynthetic process, megakaryocyte differentiation, positive regulation of osteoblast proliferation, p53 binding, negative regulation of bone mineralization, myeloid cell differentiation, cell development, Sertoli cell development, eosinophil differentiation, sequence-specific DNA binding transcription factor activity, transcription regulatory region sequence-specific DNA binding, sequence-specific DNA binding RNA polymerase II transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific DNA binding, basophil differentiation, RNA polymerase II transcription factor binding, enhancer sequence-specific DNA binding, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in negative regulation of transcription, RNA polymerase II regulatory region sequence-specific DNA binding, dendritic cell differentiation, negative regulation of transcription regulatory region DNA binding, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription, transcriptional activation by promoter-enhancer looping, eosinophil fate commitment, regulation of definitive erythrocyte differentiation
InterPro Term TF_GATA-1/2/3, Znf_GATA
Gene-Disease Assocation DYSERYTHROPOIETIC ANEMIA WITH THROMBOCYTOPENIA, DOWN SYNDROME, THROMBOCYTOPENIA, PLATELET DYSFUNCTION, HEMOLYSIS, AND IMBALANCED, ANEMIA, X-LINKED, WITHOUT THROMBOCYTOPENIA
UniProt Accession P15976, C9JJR4, B7WNQ9
Search EB-eye ENSG00000102145
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MEXP-433, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-22639, E-GEOD-19639, E-GEOD-2450, ... (18 experiments)

Factor Value U/D Experiments
K562
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
THP1
1
E-MTAB-37
hct116
1
E-MTAB-62
H1672
1
E-MTAB-62
lncap cells
1
E-MTAB-62
HCC1599
1
E-MTAB-37
92 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, E-GEOD-2822, E-GEOD-11755, ... (29 experiments)

Factor Value U/D Experiments
stromal cell
3
E-GEOD-10797, E-MEXP-2034, E-GEOD-1460
CD4+ T cell
2
E-MEXP-1600, E-GEOD-16190
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
endothelial cell
2
E-GEOD-19240, E-GEOD-3920
M1 macrophage
1
E-GEOD-5099
52 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-GEOD-6872, E-GEOD-15960, E-GEOD-1869, ... (38 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
4
E-MTAB-37, E-GEOD-96, E-MTAB-62, E-GEOD-5550
acute promyelocytic leukemia
3
E-GEOD-1729, E-MTAB-62, E-GEOD-96
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-96
acute lymphoblastic leukemia
2
E-MTAB-62, E-GEOD-96
chronic myelogenous leukemia K562
2
E-AFMX-5, E-TABM-145
normal
8
9
E-GEOD-5550, E-GEOD-6338, E-TABM-702, E-GEOD-5390, E-TABM-276, ... (17 experiments)
112 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-6907, E-GEOD-412, E-GEOD-3026, ... (11 experiments)

Factor Value U/D Experiments
none
3
E-GEOD-412, E-GEOD-5824, E-GEOD-2803
vanadium pentoxide
1
E-GEOD-5339
saline
1
E-GEOD-3026
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
BCR/ABL1
1
E-GEOD-15811
bacterial endotoxin
1
1
E-GEOD-3284
14 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-4619, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-TABM-321, E-GEOD-17347

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20540, E-MEXP-1446, E-GEOD-22278, E-MEXP-1103, E-MEXP-2146 ... (5 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-20876, ... (31 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-980

Injury
studied in E-GEOD-19743

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-2487

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-18995

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Processing time: 0.409 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM